(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Dialysis Unit, part of the Division of Nephrology and Hypertension, is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty members.
Bradley P. Dixon, MD Director, Nephrology Clinical Laboratory 513-636-4531 firstname.lastname@example.org
Director, Nephrology Clinical Laboratory
Pediatric Nephrologist, Division of Nephrology and Hypertension
Assistant Professor, UC Department of Pediatrics
DNA damage response; DNA repair; hyperosmolal microenvironments; atypical hemolytic uremic syndrome; thrombotic microangiopathies; complement-mediated renal diseases.
Visit the Dixon Lab.
Bradley Dixon, MD, joined the faculty in the Division of Nephrology and Hypertension at Cincinnati Children's within the UC College of Medicine in 2006. He has received support for his research from a William Cooper Procter Pediatric Research Award in 2006, a Child Health Research Career Development Award (K12) in 2009, and is currently funded by a K08 through the National Institute of Diabetes, Digestive and Kidney Diseases. Dr. Dixon’s research interests focus on the effects of hyperosmolal microenvironments such as the renal medulla and urinary bladder upon vital cellular processes such as the DNA damage response pathway and activation of cell cycle checkpoints and apoptosis. This research focus attempts to understand the susceptibility of the gastrointestinal tissues used in bladder reconstructions to carcinogenesis.
In addition to his basic science research interests, Dr. Dixon has a clinical research interest in thrombotic microangiopathies such as atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), and is an investigator in a number of clinical trials and registries for these diseases. Dr. Dixon is also involved in clinical research studying cystic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD).
BA: College of Wooster, Wooster, OH, 1995.
MD: University of Tennessee, Memphis, 1999.
Residency: Cincinnati Children's Hospital Medical Center, 1999-2002.
Chief Residency: Cincinnati Childrens Hospital Medical Center, 2002-2003.
Fellowship: Cincinnati Childrens Hospital Medical Center, 2003-2006.
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19;122(12):2003-7.
Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, Quilliam LA, Bissler JJ. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Renal Physiol. 2012 Sep 15;303(6):F831-44.
Dixon BP, Henry J, Siroky BJ, Chu A, Groen PA, Bissler JJ. Cell Cycle Control and DNA Damage Response of Conditionally Immortalized Urothelial Cells. PLoS ONE. 2011 Jan 28;6(1):e16595.
Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15-20.
Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010 Mar;10(3):687-91.
Dixon BP, Chu A, Henry J, Kim R, Bissler JJ. Increased cancer risk of augmentation cystoplasty: possible role for hyperosmolal microenvironment on DNA damage recognition. Mutat Res. 2009 Nov 2;670(1-2):88-95.
Dixon BP, Lu L, Chu A, Bissler JJ. RecQ and RecG helicases have distinct roles in maintaining the stability of polypurine.polypyrimidine sequences. Mutat Res. 2008 Aug 25;643(1-2):20-8.
Dixon BP, McEnery P, Goebel J. Immunobiology of paediatric renal transplantation. Progress in Paediatric Urology. 2008;10:165-182.
Bissler JJ, Dixon BP. A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol. 2005 May;20(5):558-66.
Dixon BP, Devarajan P, Mitsnefes M. Neonatal renovascular hypertension due to prenatal traumatic retroperitoneal hematoma. Pediatr Nephrol. 2005 May;20(5):670-2.
Stuart L. Goldstein, MD, FAAP, FNKF Director, Center for Acute Care Nephrology 513-803-3295 email@example.com
Director, Center for Acute Care Nephrology
Medical Director, Pheresis Service
Co-Medical Director, Heart Institute Research Core
Medical Director, Dialysis Unit
Professor, UC Department of Pediatrics
Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity
Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI.
Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.
MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.
Residency: Baylor College of Medicine, Houston, TX.
Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.
Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis. Principal Investigator. Casey Lee Ball Foundation. Jan 2010–Dec 2020.
Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Gambro Renal Products. Nov 2011-Jan 2017.
Clinical Evaluation of the Prismaflex™ HF20 Set and Prismaflex™Control Unit Version 5.10 Software for Acute Continuous Renal Replacement Therapy (CRRT) in Children. Principal Investigator. Gambro Renal Products, Inc. Mar 2014–Mar 2016.
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care. Principal Investigator. NICHD Pediatric Trials Network-POPS. Feb 2013–Feb 2017.
Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections (SCAMP Trial). Principal Investigator. NICHD-2013-ABS01 Pediatric Trials Network. May 2014–Sep 2017.
Recombinant Erythropoietin Protects Against Kidney Disease. Principal Investigator. National Institutes of Health. Sep 2014–Aug 2019.
Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Agency for Healthcare Research and Quality. Apr 2015–Mar 2018.
David K. Hooper, MD, MS Medical Director of Kidney Transplantation 513-636-4531 firstname.lastname@example.org
Medical Director of Kidney Transplantation
Nephrology; kidney transplantation; quality improvement
Jointly appointed in the Division of Nephrology and Hypertension and the James M. Anderson Center for Health Systems Excellence at Cincinnati Children’s Hospital Medical Center within the UC Department of Pediatrics, Dr. Hooper's aim is to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of reliable healthcare systems.
Dr. Hooper's research training includes a master's degree in clinical and translational research from the University of Cincinnati, in addition to advanced training in quality improvement methodology through the Quality Scholars in Healthcare Transformation program at Cincinnati Children’s.
Dr. Hooper's career focus is to combine clinical outcomes research with quality improvement to reliably prevent cardiovascular disease, the leading cause of long-term death and disability in pediatric transplant recipients.
MD: University of Utah, Salt Lake City, Utah, 2003.
Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2006.
Chief Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2007.
MS: University of Cincinnati, Cincinnati, Ohio, 2010.
Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2010; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, Ohio, 2011.
Certification: Pediatrics, 2006.
Hooper DK, Kirby C, Margolis P, Goebel J. Reliable Individualized Monitoring Improves Cholesterol Control in Kidney Transplant Recipients. Pediatrics. 2013 Apr;131(4):e1271-9.
Hooper DK, Williams JC, Carle AC, Amaral S, Chand DH, Ferris ME, Patel HP, Licht C, Barletta GM, Bastian V, Mitsnesfes M, Patel UD. The Quality of Cardiovascular Disease Care and Formal Transition for Adolescents with Kidney Disease. Pediatr Nephrol. 2013 Jun;28(6):939-49.
Hooper DK, Fukuda T, Logan B, Gardiner R, Roy-Chaudhury A, Kirby C, Vinks A, Goebel J. Risk of Tacrolimus Toxicity in CYP3A5 Non-Expressors Treated with Intravenous Nicardipine After Kidney Transplantation. Transplantation. 2012 Apr;93(8):806-812.
Saldaña SN, Hooper DK, Froehlich TE, Campbell KM, Prows CA, Sadhasivam s, Nick TG, Seid M, Vinks AA, Glauser TA. Characteristics of Successful Recruitment in Prospective Pediatric Pharmacogenetic Studies. Clinical Therapeutics. 2011 Feb;15:88-95.
Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95.
Kaplan HC, Brady PW, Dritz MC, Hooper DK, Linam WM, Froehle CM, Margolis P. The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q. 2010 Dec;88(4):500-59.
Hooper DK. The Impact of CYP3A5 Genotype on the Interaction Between Tacrolimus and Intravenous Nicardipine in Kidney Transplant Recipients. University of Cincinnati. 2010 Aug 17.
Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg. 2005 Feb;79(2):641-4.
Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer. 2003 Aug 15;98(4):841-53.
Lirazan MB, Hooper D, Corpuz GP, Ramilo CA, Bandyopadhyay P, Cruz LJ, Olivera BM. The spasmodic peptide defines a new conotoxin superfamily. Biochemistry. 2000 Feb 22;39(7):1583-8.
Edward J. Nehus, MD, MS Pediatric Nephrologist, Division of Nephrology 513-636-4531 email@example.com
Pediatric Nephrologist, Division of Nephrology
Critical care nephrology; chronic kidney disease
Edward conducted and published a cross-sectional study which investigated the association of serum resistin with cardiovascular risk factors in children with chronic kidney disease. In addition, he recently published a study evaluating the outcomes steroid-avoidance protocols in pediatric kidney transplant recipients. He continues to be the primary investigator for ongoing studies that explore pharmacokinetic alterations in critically ill children receiving continuous renal replacement therapy.
MD: University of Toledo, Toledo, OH, 2002.
MS: University of Cincinnati, Cincinnati, OH, 2011.
Residency: Pediatrics, Nationwide Children’s Hospital, Columbus, OH.
Certification: Pediatrics, 2009.
Fellowship: Pediatric Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Nehus E, Goebel J, Abraham E. Outcomes of steroid-avoidance protocols in pediatric kidney transplant recipients. Am J Transplant. 2012 Dec;12(12):3441-8.
Nehus E, Furth S, Warady B, Mitsnefes M. Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort. J Pediatr. 161(2): 276-80, 2012.
Nehus E, Goebel J, Mitsnefes M, Lorts A, Laskin B. Intensive hemodialysis for cardiomyopathy associated with end-stage renal disease. Pediatr Nephrol. 26: 1909-12, 2011.
Nehus E, Devarajan P. Acute kidney injury: AKI in kidney transplant recipients—here to stay. Nat Rev Nephrol. 8:198-199, 2012.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.